Source Natural Foods and Herbal Supplements Past Earnings Performance
Past criteria checks 4/6
Source Natural Foods and Herbal Supplements's earnings have been declining at an average annual rate of -0.5%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 11.9% per year. Source Natural Foods and Herbal Supplements's return on equity is 12.3%, and it has net margins of 7.6%.
Key information
-0.5%
Earnings growth rate
-0.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.9% |
| Return on equity | 12.3% |
| Net Margin | 7.6% |
| Next Earnings Update | 14 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Source Natural Foods and Herbal Supplements makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 332 | 25 | 30 | 0 |
| 30 Jun 24 | 299 | 19 | 27 | 0 |
| 31 Mar 24 | 273 | 17 | 31 | 0 |
| 31 Dec 23 | 273 | 25 | 34 | 0 |
| 30 Sep 23 | 245 | 18 | 35 | 0 |
| 30 Jun 23 | 210 | 19 | 31 | 0 |
| 31 Mar 23 | 198 | 21 | 34 | 0 |
| 31 Dec 22 | 184 | 20 | 16 | 0 |
| 30 Sep 22 | 172 | 19 | 20 | 0 |
| 30 Jun 22 | 180 | 18 | 27 | 0 |
| 31 Mar 22 | 215 | 24 | 47 | 0 |
| 31 Dec 21 | 205 | 16 | 30 | 0 |
| 30 Sep 21 | 251 | 29 | 38 | 0 |
| 30 Jun 21 | 280 | 39 | 37 | 0 |
| 31 Mar 21 | 249 | 34 | 25 | 0 |
| 31 Dec 20 | 243 | 38 | 56 | 0 |
| 30 Sep 20 | 199 | 31 | 40 | 0 |
| 30 Jun 20 | 155 | 20 | 38 | 0 |
| 31 Mar 20 | 136 | 16 | 26 | 0 |
| 31 Dec 19 | 130 | 11 | 23 | 0 |
| 30 Sep 19 | 122 | 9 | 23 | 0 |
| 30 Jun 19 | 132 | 11 | 37 | 0 |
| 31 Mar 19 | 128 | 10 | 24 | 0 |
| 31 Dec 18 | 122 | 9 | 20 | 0 |
| 30 Sep 18 | 115 | 10 | 20 | 0 |
| 30 Jun 18 | 112 | 14 | 19 | 0 |
| 31 Mar 18 | 108 | 8 | 21 | 0 |
| 31 Dec 17 | 132 | 10 | 11 | 0 |
| 30 Sep 17 | 164 | 17 | 16 | 0 |
| 30 Jun 17 | 160 | 9 | 73 | 0 |
| 31 Mar 17 | 159 | 14 | 21 | 0 |
| 31 Dec 16 | 145 | 9 | 30 | 0 |
| 30 Sep 16 | 114 | -4 | 29 | 0 |
| 30 Jun 16 | 107 | 1 | 20 | 0 |
| 31 Mar 16 | 109 | 4 | 17 | 0 |
| 31 Dec 15 | 92 | 8 | 24 | 0 |
| 30 Sep 15 | 79 | 6 | 16 | 0 |
| 30 Jun 15 | 75 | 5 | 20 | 0 |
| 31 Mar 15 | 65 | 2 | 14 | 0 |
| 31 Dec 14 | 62 | 4 | 23 | 0 |
| 30 Sep 14 | 61 | 5 | 21 | 0 |
| 30 Jun 14 | 51 | 3 | 20 | 0 |
| 31 Mar 14 | 45 | 2 | 18 | 0 |
| 31 Dec 13 | 42 | 2 | 17 | 0 |
Quality Earnings: 531398 has high quality earnings.
Growing Profit Margin: 531398's current net profit margins (7.6%) are higher than last year (7.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531398's earnings have declined by 0.5% per year over the past 5 years.
Accelerating Growth: 531398's earnings growth over the past year (40%) exceeds its 5-year average (-0.5% per year).
Earnings vs Industry: 531398 earnings growth over the past year (40%) exceeded the Pharmaceuticals industry 20.4%.
Return on Equity
High ROE: 531398's Return on Equity (12.3%) is considered low.